亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Small Molecule for Treatment of Epilepsy, Pain, and Other Neurological Disorders

技術優勢
• Selective antagonist for kainite receptor • No other commercially available molecule with similar activity
詳細技術說明
A new class of small molecules that may be used to targetspecific AMPA* receptors #therapeutics #smallmolecules #pain #neurology
*Abstract

Over-activation of AMPA receptors contributes to the pathology of a number of neurological diseases, particularly epilepsy, neuropathic pain, and stroke. A new group of heterotricyclic molecules called "IKM" analogs have been determined to act pharmacologically as AMPA receptor antagonists. Northwestern researchers have discovered a new class of small molecules that may be used to target specific AMPA receptors. A small molecule, 2,4-epi-neodysiherbaine (2,4-epi-NDH), has been determined to act as a selective kainate receptor antagonist. 2,4-epi-NDH is a synthetic analog of a natural molecule, dysiherbaine, which is itself a rigid analog of the excitatory amino acid neurotransmitter L-glutamate. The novelty of 2,4-epi-NDH is structural in that it has altered stereochemistry at the C2 and C4 positions and thus is not strictly considered an L-glutamate congener. The molecular also exhibits a novel pharmacological profile. There currently is no commercially available small molecule with similar pharmacological activity, making 2,4-epi-neodysiherbaine a desirable candidate for therapeutic use.

*Inventors
Leanne Lash Geoffrey Swanson* Ryuichi Sakai
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備